Charles Russell Speechlys advises on the sale of Xstrahl to Risk Capital Partners
Charles Russell Speechlys has advised on the sale of Xstrahl, a medical devices business that designs and delivers effective clinical and research solutions to advance radiation oncology, to Risk Capital Partners as part of a management buyout. The firm acted for Martin Robinson, the majority shareholder and previous CEO, from whom the business was acquired.